234 related articles for article (PubMed ID: 16618770)
1. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
Kawakami K; Terabe M; Kawakami M; Berzofsky JA; Puri RK
Cancer Res; 2006 Apr; 66(8):4434-42. PubMed ID: 16618770
[TBL] [Abstract][Full Text] [Related]
2. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
3. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
Wu TY; Fleischmann WR
J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
[TBL] [Abstract][Full Text] [Related]
4. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.
Nakashima H; Fujisawa T; Husain SR; Puri RK
J Transl Med; 2010 Nov; 8():116. PubMed ID: 21067607
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
[TBL] [Abstract][Full Text] [Related]
9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
Kawakami K; Kawakami M; Husain SR; Puri RK
Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
[TBL] [Abstract][Full Text] [Related]
11. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
Yin X; Yan X; Yang Q; Cao H; Liang H
Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831
[TBL] [Abstract][Full Text] [Related]
12. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
[TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
16. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo.
Ma HL; Whitters MJ; Jacobson BA; Donaldson DD; Collins M; Dunussi-Joannopoulos K
Int Immunol; 2004 Jul; 16(7):1009-17. PubMed ID: 15184346
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
19. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2.
Chang MR; Lee WH; Choi JW; Park SO; Paik SG; Kim YS
Exp Mol Med; 2005 Jun; 37(3):240-9. PubMed ID: 16000879
[TBL] [Abstract][Full Text] [Related]
20. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
